Nicholas A. Smith

Array ( [id] => 7371942 [patent_doc_number] => 20040219143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-11-04 [patent_title] => 'Methods for recombinant immunoglobulin treatment' [patent_app_type] => new [patent_app_number] => 10/426334 [patent_app_country] => US [patent_app_date] => 2003-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4937 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0219/20040219143.pdf [firstpage_image] =>[orig_patent_app_number] => 10426334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6966493 [patent_doc_number] => 20050233390 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-10-20 [patent_title] => 'Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor' [patent_app_type] => utility [patent_app_number] => 10/410649 [patent_app_country] => US [patent_app_date] => 2003-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9268 [patent_no_of_claims] => 117 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0233/20050233390.pdf [firstpage_image] =>[orig_patent_app_number] => 10410649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7033104 [patent_doc_number] => 20050031613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-02-10 [patent_title] => 'Therapeutic agent for patients having human FcgammaRIIIa' [patent_app_type] => utility [patent_app_number] => 10/409608 [patent_app_country] => US [patent_app_date] => 2003-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 60036 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0031/20050031613.pdf [firstpage_image] =>[orig_patent_app_number] => 10409608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 925789 [patent_doc_number] => 07317087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2008-01-08 [patent_title] => 'Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof' [patent_app_type] => utility [patent_app_number] => 10/508374 [patent_app_country] => US [patent_app_date] => 2003-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21878 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/317/07317087.pdf [firstpage_image] =>[orig_patent_app_number] => 10508374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6977443 [patent_doc_number] => 20050287159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-12-29 [patent_title] => 'Treatment methods for eotaxin mediated inflammatory conditons' [patent_app_type] => utility [patent_app_number] => 10/509292 [patent_app_country] => US [patent_app_date] => 2003-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6931 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0287/20050287159.pdf [firstpage_image] =>[orig_patent_app_number] => 10509292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6829207 [patent_doc_number] => 20030180265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-25 [patent_title] => 'Modulating angiogenesis' [patent_app_type] => new [patent_app_number] => 10/392439 [patent_app_country] => US [patent_app_date] => 2003-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9156 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0180/20030180265.pdf [firstpage_image] =>[orig_patent_app_number] => 10392439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6846844 [patent_doc_number] => 20030166011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-04 [patent_title] => 'Monoclonal antibody against connective tissue growth factor and medicinal uses thereof' [patent_app_type] => new [patent_app_number] => 10/390986 [patent_app_country] => US [patent_app_date] => 2003-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 38128 [patent_no_of_claims] => 82 [patent_no_of_ind_claims] => 36 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20030166011.pdf [firstpage_image] =>[orig_patent_app_number] => 10390986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 201950 [patent_doc_number] => 07632495 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-12-15 [patent_title] => 'Use of soluble fgl2 as an immunosuppressant' [patent_app_type] => utility [patent_app_number] => 10/504328 [patent_app_country] => US [patent_app_date] => 2003-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 18 [patent_no_of_words] => 16769 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/632/07632495.pdf [firstpage_image] =>[orig_patent_app_number] => 10504328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6829229 [patent_doc_number] => 20030180287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-25 [patent_title] => 'Polypeptide formulation' [patent_app_type] => new [patent_app_number] => 10/376576 [patent_app_country] => US [patent_app_date] => 2003-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 7811 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0180/20030180287.pdf [firstpage_image] =>[orig_patent_app_number] => 10376576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6663649 [patent_doc_number] => 20030202975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-10-30 [patent_title] => 'Reagents and treatment methods for autoimmune diseases' [patent_app_type] => new [patent_app_number] => 10/372481 [patent_app_country] => US [patent_app_date] => 2003-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 15433 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0202/20030202975.pdf [firstpage_image] =>[orig_patent_app_number] => 10372481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7429501 [patent_doc_number] => 20040001828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-01 [patent_title] => 'Treatment methods using anti-CD22 antibodies' [patent_app_type] => new [patent_app_number] => 10/371797 [patent_app_country] => US [patent_app_date] => 2003-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 14369 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0001/20040001828.pdf [firstpage_image] =>[orig_patent_app_number] => 10371797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7438105 [patent_doc_number] => 20040002587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-01 [patent_title] => 'Fc region variants' [patent_app_type] => new [patent_app_number] => 10/370749 [patent_app_country] => US [patent_app_date] => 2003-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 49476 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0002/20040002587.pdf [firstpage_image] =>[orig_patent_app_number] => 10370749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6740204 [patent_doc_number] => 20030157573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-08-21 [patent_title] => 'Use of Axl receptor for diagnosis and treatment of renal disease' [patent_app_type] => new [patent_app_number] => 10/365135 [patent_app_country] => US [patent_app_date] => 2003-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 18791 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0157/20030157573.pdf [firstpage_image] =>[orig_patent_app_number] => 10365135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 623788 [patent_doc_number] => 07138496 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-11-21 [patent_title] => 'Human monoclonal antibodies against human CXCR4' [patent_app_type] => utility [patent_app_number] => 10/360828 [patent_app_country] => US [patent_app_date] => 2003-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 25 [patent_no_of_words] => 30393 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/138/07138496.pdf [firstpage_image] =>[orig_patent_app_number] => 10360828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 196468 [patent_doc_number] => 07638325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-12-29 [patent_title] => 'Activation and expansion of T-cells using an engineered multivalent signaling platform' [patent_app_type] => utility [patent_app_number] => 10/336224 [patent_app_country] => US [patent_app_date] => 2003-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 31398 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/638/07638325.pdf [firstpage_image] =>[orig_patent_app_number] => 10336224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6842522 [patent_doc_number] => 20030147869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-08-07 [patent_title] => 'System and methods for promoting expansion of polyclonal and antigen-specific cytotoxic T lymphocytes in response to artificial antigen presenting cells' [patent_app_type] => new [patent_app_number] => 10/336135 [patent_app_country] => US [patent_app_date] => 2003-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 20080 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0147/20030147869.pdf [firstpage_image] =>[orig_patent_app_number] => 10336135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6761259 [patent_doc_number] => 20030124621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-07-03 [patent_title] => 'Method of assaying the function of fc fragment of antibody' [patent_app_type] => new [patent_app_number] => 10/312669 [patent_app_country] => US [patent_app_date] => 2002-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4384 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0124/20030124621.pdf [firstpage_image] =>[orig_patent_app_number] => 10312669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7046122 [patent_doc_number] => 20050250717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-11-10 [patent_title] => 'Chromatin remodeling protein as a marker expressed by stromal progenitor cells' [patent_app_type] => utility [patent_app_number] => 10/499715 [patent_app_country] => US [patent_app_date] => 2002-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 16356 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0250/20050250717.pdf [firstpage_image] =>[orig_patent_app_number] => 10499715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6847401 [patent_doc_number] => 20030166568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-04 [patent_title] => 'Organic compounds' [patent_app_type] => new [patent_app_number] => 10/221984 [patent_app_country] => US [patent_app_date] => 2002-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3715 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20030166568.pdf [firstpage_image] =>[orig_patent_app_number] => 10221984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7463788 [patent_doc_number] => 20040101528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-05-27 [patent_title] => 'Type I IL-1 receptors' [patent_app_type] => new [patent_app_number] => 10/309512 [patent_app_country] => US [patent_app_date] => 2002-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 18011 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0101/20040101528.pdf [firstpage_image] =>[orig_patent_app_number] => 10309512 [rel_patent_id] =>[rel_patent_doc_number] =>)